Division of Hematology and Medical Oncology, Weill Cornell Medical College New York, NY, USA.
Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012.
Circulating tumor cells (CTCs) are tumor cells found in the peripheral blood that putatively originate from established sites of malignancy and likely have metastatic potential. Analysis of CTCs has demonstrated promise as a prognostic marker as well as a source of identifying potential targets for novel therapeutics. Isolation and characterization of these cells for study, however, remain challenging owing to their rarity in comparison with other cellular components of the peripheral blood. Several techniques that exploit the unique biochemical properties of CTCs have been developed to facilitate their isolation. Positive selection of CTCs has been achieved using microfluidic surfaces coated with antibodies against epithelial cell markers or tumor-specific antigens such as EpCAM or prostate-specific membrane antigen (PSMA). Following isolation, characterization of CTCs may help guide clinical decision making. For instance, molecular and genetic characterization may shed light on the development of chemotherapy resistance and mechanisms of metastasis without the need for a tissue biopsy. This paper will review novel isolation techniques to capture CTCs from patients with advanced prostate cancer, as well as efforts to characterize the CTCs. We will also review how these analyzes can assist in clinical decision making.
The study of CTCs provides insight into the molecular biology of tumors of prostate origin that will eventually guide the development of tailored therapeutics. These advances are predicated on high yield and accurate isolation techniques that exploit the unique biochemical features of these cells.
循环肿瘤细胞(CTCs)是在外周血液中发现的肿瘤细胞,推测来源于已建立的恶性肿瘤部位,并且可能具有转移潜力。CTCs 的分析已被证明是一种有前途的预后标志物,也是识别潜在治疗靶点的来源。然而,由于其在外周血液中其他细胞成分中的稀有性,这些细胞的分离和鉴定仍然具有挑战性。已经开发了几种利用 CTCs 独特生化特性的技术来促进其分离。CTCs 的阳性选择是通过用针对上皮细胞标志物或肿瘤特异性抗原(如 EpCAM 或前列腺特异性膜抗原(PSMA)的抗体涂覆的微流控表面来实现的。分离后,CTCs 的特征分析可能有助于指导临床决策。例如,分子和遗传特征分析可以揭示化疗耐药性的发展和转移机制,而无需组织活检。本文将综述从晚期前列腺癌患者中捕获 CTCs 的新型分离技术,以及对 CTCs 进行特征分析的努力。我们还将回顾这些分析如何协助临床决策。
CTCs 的研究提供了对源自前列腺的肿瘤的分子生物学的深入了解,最终将指导针对这些肿瘤的个体化治疗的发展。这些进展取决于能够利用这些细胞独特生化特性的高产量和准确的分离技术。